Bank of New York Mellon
ALGS icon

Bank of New York Mellon’s Aligos Therapeutics ALGS Stock Holding History

Bank of New York Mellon’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,065
Closed -$111K – 4581
2022
Q1 		$111K Hold
2,065
– – ﹤0.01% 4388
2021
Q4 		$612K Buy
2,065
+125
+6% +$45.6K ﹤0.01% 3666
2021
Q3 		$752K Buy
1,940
+123
+7% +$48.7K ﹤0.01% 3567
2021
Q2 		$926K Buy
1,817
+546
+43% +$348K ﹤0.01% 3472
2021
Q1 		$723K Buy
1,271
+67
+6% +$44.6K ﹤0.01% 3504
2020
Q4 		$832K Buy
+1,204
New +$586K ﹤0.01% 3353

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon's ALGS Position: Q2 2022 in Review

Bank of New York Mellon sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 2,065 shares — an estimated $111K sold.

Bank of New York Mellon first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $926K in Q2 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Bank of New York Mellon reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 2,065 Aligos Therapeutics shares in Q2 2022, an estimated $111K.
  • Bank of New York Mellon first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
  • Bank of New York Mellon's Aligos Therapeutics position peaked at $926K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.